<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations><gtr:collaborator url="http://gtr.ukri.org:80/organisation/3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9"><gtr:id>3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9</gtr:id><gtr:name>University of Oxford</gtr:name><gtr:address><gtr:line1>University Chest</gtr:line1><gtr:line2>Wellington Square</gtr:line2><gtr:line4>Oxford</gtr:line4><gtr:postCode>OX1 2JD</gtr:postCode><gtr:region>South East</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/31C8C3D6-0F45-4639-8C94-78C0C503AB52"><gtr:id>31C8C3D6-0F45-4639-8C94-78C0C503AB52</gtr:id><gtr:name>Genethon</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/72A01FCA-EC02-4B8C-BFAC-3E4BD601C455"><gtr:id>72A01FCA-EC02-4B8C-BFAC-3E4BD601C455</gtr:id><gtr:name>International Collaborative Effort for DMD</gtr:name></gtr:collaborator></gtr:collaborations><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/78308CAA-8483-45C0-A280-0AB4B6AD9D35"><gtr:id>78308CAA-8483-45C0-A280-0AB4B6AD9D35</gtr:id><gtr:name>Medical Research Council</gtr:name><gtr:department>Medical Research Council</gtr:department><gtr:address><gtr:line1>Polaris House</gtr:line1><gtr:line2>North Star Avenue</gtr:line2><gtr:postCode>SN2 1FL</gtr:postCode><gtr:region>South West</gtr:region></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/78308CAA-8483-45C0-A280-0AB4B6AD9D35"><gtr:id>78308CAA-8483-45C0-A280-0AB4B6AD9D35</gtr:id><gtr:name>Medical Research Council</gtr:name><gtr:address><gtr:line1>Polaris House</gtr:line1><gtr:line2>North Star Avenue</gtr:line2><gtr:postCode>SN2 1FL</gtr:postCode><gtr:region>South West</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9"><gtr:id>3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9</gtr:id><gtr:name>University of Oxford</gtr:name><gtr:address><gtr:line1>University Chest</gtr:line1><gtr:line2>Wellington Square</gtr:line2><gtr:line4>Oxford</gtr:line4><gtr:postCode>OX1 2JD</gtr:postCode><gtr:region>South East</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/31C8C3D6-0F45-4639-8C94-78C0C503AB52"><gtr:id>31C8C3D6-0F45-4639-8C94-78C0C503AB52</gtr:id><gtr:name>Genethon</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/72A01FCA-EC02-4B8C-BFAC-3E4BD601C455"><gtr:id>72A01FCA-EC02-4B8C-BFAC-3E4BD601C455</gtr:id><gtr:name>International Collaborative Effort for DMD</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/E152F8DC-B44A-4592-BCC4-42CF9258AD52"><gtr:id>E152F8DC-B44A-4592-BCC4-42CF9258AD52</gtr:id><gtr:firstName>Kay</gtr:firstName><gtr:surname>Davies</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=G0801763"><gtr:id>5BCBF472-9D16-42B2-BF25-2D152DC06624</gtr:id><gtr:title>Upgrading U7snRNA to complete efficient rescue of dystrophin by exon-skipping in DMD patients</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Research Grant</gtr:grantCategory><gtr:grantReference>G0801763</gtr:grantReference><gtr:abstractText>Abstracts are not currently available in GtR for all funded research. This is normally because the abstract was not required at the time of proposal submission, but may be because it included sensitive information such as personal details.</gtr:abstractText><gtr:technicalSummary>Most cases of Duchenne muscular dystrophy (DMD) are caused by mutations that disrupt the dystrophin mRNA reading frame. In many cases, skipping of a single exon could restore the reading frame, giving rise to a shorter but still functional quasi-dystrophin protein. This exon skipping approach using oligonucleotides is currently in clinical trial for DMD, but only applies to a few patients. We wish to develop constructs which will be applicable to more patients using a viral approach. It has previously been proposed to use small nuclear RNAs, especially U7snRNA, to shuttle antisense sequences designed to mask key elements involved in the splicing of targeted exons.
Our proposed project focuses on the upgrading of U7snRNA to complete rescue of dystrophin by exon-skipping in DMD patients. We therefore propose the development of bifunctional U7snRNAs carrying a complementary sequence to the targeted exon and a free tail harbouring canonical binding sites for the heterogeneous nuclear ribonucleoproteins A1/A2 (hnRNP) that are powerful splicing repressors. The presence of this generic strong silencer tail could indeed circumvent the always tricky and time-consuming specific optimization required for each new exon-target. In addition to the optimization of the mono-exon-skipping, we propose to investigate the possibility of inducing multi-skipping. This approach could considerably increase the number of eligible patients and would reduce the number of U7 constructs that have to be made in order to treat the different kind of mutations found in DMD patients.
The new U7 constructs will be evaluated both in vitro in cells from DMD patients and in vivo in a transgenic humanized mouse model, specifically imported from the Netherlands to our facility. The newly established viral vector production platform in the department will provide the perfect environment to produce the lentiviral and AAV vectors required for both the in vitro and in vivo evaluation of these constructs.
The preliminary results obtained on exon 51 are very encouraging and provide evidence that bifunctional U7snRNA can achieve efficient exon-skipping in myoblasts from DMD patients. Confirmation of their efficiency on other exons and development of the multi-skipping constructs would therefore offer very promising tools for clinical treatment of DMD.</gtr:technicalSummary><gtr:fund><gtr:end>2010-09-30</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2008-10-01</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>155534</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs><gtr:collaborationOutput><gtr:collaboratingOrganisation>Genethon</gtr:collaboratingOrganisation><gtr:country>France, French Republic</gtr:country><gtr:description>Exon skipping and miRNA analysis in DMD</gtr:description><gtr:id>585042B6-85C5-4E2E-80E1-BDBA92AA49CE</gtr:id><gtr:impact>Publication: Crisp Alastair (Feb, 2011) Diaphragm rescue alone prevents heart dysfunction in dystrophic mice., Human molecular genetics 20, 3, 413-21</gtr:impact><gtr:outcomeId>mkmSnYuVxX1-2</gtr:outcomeId><gtr:partnerContribution>Preparation and evaluation of peptide conjugated oligonucleotides for exon skipping</gtr:partnerContribution><gtr:piContribution>Double knock-out mouse model of DMD and delivery of antisense oligonucleotides to mouse model</gtr:piContribution><gtr:sector>Public</gtr:sector><gtr:start>2010-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Oxford</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Department of Physiology, Anatomy and Genetics</gtr:department><gtr:description>Exon skipping and miRNA analysis in DMD</gtr:description><gtr:id>6C339F2B-A8EF-4B7B-96F2-B1DB024CA520</gtr:id><gtr:impact>Publication: Crisp Alastair (Feb, 2011) Diaphragm rescue alone prevents heart dysfunction in dystrophic mice., Human molecular genetics 20, 3, 413-21</gtr:impact><gtr:outcomeId>mkmSnYuVxX1-1</gtr:outcomeId><gtr:partnerContribution>Preparation and evaluation of peptide conjugated oligonucleotides for exon skipping</gtr:partnerContribution><gtr:piContribution>Double knock-out mouse model of DMD and delivery of antisense oligonucleotides to mouse model</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2010-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>International Collaborative Effort for DMD</gtr:collaboratingOrganisation><gtr:country>Global</gtr:country><gtr:description>ICE - International Collaborative Effort for DMD</gtr:description><gtr:id>71C3C312-95F3-4EC5-BB2E-461108ECEDFE</gtr:id><gtr:impact>We have developed a method for increasing the efficiency of exon skipping.</gtr:impact><gtr:outcomeId>565F6E9745E-1</gtr:outcomeId><gtr:partnerContribution>They send us Exon skipping constructs for us to test in the utrophin/dystrophin double mutant mouse</gtr:partnerContribution><gtr:piContribution>We contribute new constructs for more efficient exon skipping.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2008-01-01</gtr:start></gtr:collaborationOutput></gtr:collaborationOutputs><gtr:disseminationOutputs><gtr:disseminationOutput><gtr:description>Interview for Oxford Mail for Town and Gown Fun Run. 2013</gtr:description><gtr:form>A press release, press conference or response to a media enquiry/interview</gtr:form><gtr:geographicReach>Local</gtr:geographicReach><gtr:id>1A90C227-1B30-4A4C-8454-E07BA2A13965</gtr:id><gtr:impact>Interview for Oxford Mail for Town and Gown Fun Run. 27th March

Greater local public awareness of research on Muscular Dystrophy being done by the Unit and MRC</gtr:impact><gtr:outcomeId>oWcmy8QLyUw</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:presentationType>Keynote/Invited Speaker</gtr:presentationType><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2013</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Presentation at Action Duchenne meeting 2010</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>BE8D943E-A7EF-4F05-8503-AA4A27D33D41</gtr:id><gtr:impact>Talk entitled: &amp;quot;Multi Exon Skipping Approach for DMD Therapy&amp;quot;, presented by AG at Action Duchenne 8th International Conference, London - November

Greater awareness by charity and patient group of latest research on Duchenne Muscular Dystrophy being undertaken by the Unit and MRC</gtr:impact><gtr:outcomeId>VAqm5qhtecZ</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Participants in your research and patient groups</gtr:primaryAudience><gtr:year>2010</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Science interview with journalist from The Times</gtr:description><gtr:form>A press release, press conference or response to a media enquiry/interview</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>7F854274-51E3-45EB-B1D4-5169DC9C5A3D</gtr:id><gtr:impact>Science Interview with Mark Henderson from the Times on exon skipping strategy, Oct 2009. Review appeared in The Times, Science Blog.

More patient awareness. Patients contacted the Unit</gtr:impact><gtr:outcomeId>462FEA7EFFF</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2009</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Speaker, Muscular Dystrophy Campaign President's Club Tribute Lunch, May 2012</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>B8648313-6EFE-49FC-9165-EEEFDFD9B240</gtr:id><gtr:impact>5 minute talk, Muscular Dystrophy Campaign President's Club Tribute Lunch - 23rd May.

Greater national awareness of muscular dystrophy research and work of both the FGU and MRC</gtr:impact><gtr:outcomeId>fJGxgjH88MP</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:presentationType>Keynote/Invited Speaker</gtr:presentationType><gtr:primaryAudience>Participants in your research and patient groups</gtr:primaryAudience><gtr:year>2012</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Lecture to Parent/Patient Group 2010</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>2411AF4B-E489-4E3A-8B7F-467FE4732FE5</gtr:id><gtr:impact>Lecture entitled &amp;quot;U7 and multi-exon skipping&amp;quot; - delivered to Parent Project Muscular Dystrophy - PPMD DMD Therapeutic Development Conference - Denver, USA

Greater interntional awareness of DMD patents/parents of muscular dystrophy research being undertaken by the Unit/MRC</gtr:impact><gtr:outcomeId>hZxTjqyTBvp</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Participants in your research and patient groups</gtr:primaryAudience><gtr:year>2010</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Presentation at Action Duchenne meeting 2011</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>172B5C1B-DF9B-46AB-85FE-B19DA37122AD</gtr:id><gtr:impact>&amp;quot;Light at the end of the tunnel?&amp;quot; - talk by Prof Kay Davies at the Action Duchenne International Conference, Holiday Inn Bloomsbury, London - 4th November



Greater awareness by charity and patient group of latest research on Duchenne Muscular Dystrophy being undertaken by the Unit and MRC</gtr:impact><gtr:outcomeId>pDrNEUVi2Ax</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Participants in your research and patient groups</gtr:primaryAudience><gtr:year>2011</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Laboratory visit by members of Muscular Dystrophy Campaign, 2013</gtr:description><gtr:form>Participation in an open day or visit at my research institution</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>E0A04532-AE80-4B95-B9E4-C51F4EF9CF25</gtr:id><gtr:impact>Visit to FGU labs by members of Muscular Dystrophy Campaign. Presentations by Prof Kay Davies and Dr Rebecca Fairclough followed by tour of the laboratory.
19 August 2013

Greater awareness of research on muscular dystrophy being undertaken by the Unit and MRC and understanding of the laboratory environment in which MDC funded research is being undertaken</gtr:impact><gtr:outcomeId>Ng2CABsKS6k</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:presentationType>Keynote/Invited Speaker</gtr:presentationType><gtr:primaryAudience>Participants in your research and patient groups</gtr:primaryAudience><gtr:year>2013</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Lecture - Kingston University, June 2012</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>Regional</gtr:geographicReach><gtr:id>92802821-E1FD-4EFE-91CF-D6A38AA78B36</gtr:id><gtr:impact>Talk entitled &amp;quot;Progress in therapy for Duchenne muscular dystrophy: reason for optimism&amp;quot; - Kingston University Rose Lecture Series. 


Greater awareness of research on muscular dystrophy being undertaken by the Unit and MRC for patient groups and the general public</gtr:impact><gtr:outcomeId>RMrGpLfqnFF</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:presentationType>Keynote/Invited Speaker</gtr:presentationType><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2012</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Interview to help with Eli's Fund 2012</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>36BB9C8E-3F89-4230-87D1-4A2D396D5AA2</gtr:id><gtr:impact>Interview to help with Eli's Fund.


To raise awareness of muscular dystrophy and ongoing research to tackle disease</gtr:impact><gtr:outcomeId>UBjk2LRRanb</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:presentationType>Keynote/Invited Speaker</gtr:presentationType><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2012</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Interview for BBC News May 2011</gtr:description><gtr:form>A press release, press conference or response to a media enquiry/interview</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>4D7FE686-1FA8-4E1C-8BD8-3D8E6A190C67</gtr:id><gtr:impact>&amp;quot;Drug offers hope for treating muscular dystrophy&amp;quot; An interview with BBC News, May 5th 2011

Greater international awareness of muscular dystrophy research and work of both the FGU and MRC</gtr:impact><gtr:outcomeId>EV6ru5wdRyg</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2011</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>MRC Centenary Oxford Science Festival, 2013</gtr:description><gtr:form>Participation in an activity, workshop or similar</gtr:form><gtr:geographicReach>Local</gtr:geographicReach><gtr:id>057E7610-B4A6-4DF2-A931-C1B11B49E093</gtr:id><gtr:impact>Prof Kay Davies and members of her group helped to man a stall on behalf of Muscular Dystrophy Campaign at the MRC Centenary mini-science festival held in Oxford, 22 June 2013.

Greater local public awareness of muscular dystrophy research and work of both the FGU and MRC</gtr:impact><gtr:outcomeId>EAUvPP1cKck</gtr:outcomeId><gtr:partOfOfficialScheme>true</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2013</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Talk at &quot;Save our Sons Gala Dinner&quot;, Help Cure DMD, Australia 2013</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>CB098E97-599F-414A-B198-2FE74162E016</gtr:id><gtr:impact>Speech at &amp;quot;Save our Sons Gala Dinner&amp;quot;, Help Cure DMD, Randwick, Sydney, Australia - 31st August.

Greater international awareness of muscular dystrophy research and work of both the FGU and MRC</gtr:impact><gtr:outcomeId>GR51du4aoTY</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:presentationType>Keynote/Invited Speaker</gtr:presentationType><gtr:primaryAudience>Participants in your research and patient groups</gtr:primaryAudience><gtr:year>2013</gtr:year></gtr:disseminationOutput></gtr:disseminationOutputs><gtr:exploitationOutputs/><gtr:furtherFundingOutputs><gtr:furtherFundingOutput><gtr:amountPounds>170045</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>MDC - Optimization of U7 snRNA vectors for therapy of DMD</gtr:description><gtr:end>2011-09-02</gtr:end><gtr:fundingOrg>Muscular Dystrophy UK</gtr:fundingOrg><gtr:id>F710D2CB-2E67-4315-BCEF-805545265D71</gtr:id><gtr:outcomeId>1071EB80FE40</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2009-10-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>70000</gtr:amountPounds><gtr:country>France, French Republic</gtr:country><gtr:currCode>EUR</gtr:currCode><gtr:currCountryCode>Austria</gtr:currCountryCode><gtr:currLang>de_AT</gtr:currLang><gtr:description>ICE - International Collaborative Effort for DMD</gtr:description><gtr:end>2012-09-02</gtr:end><gtr:fundingOrg>Duchenne Parent Project France (DPPF)</gtr:fundingOrg><gtr:id>CE0AD7A5-86B6-4241-BE60-D41A52B962AD</gtr:id><gtr:outcomeId>nmphfQkhExH</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2011-10-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>60000</gtr:amountPounds><gtr:country>Monaco, Principality of</gtr:country><gtr:currCode>EUR</gtr:currCode><gtr:currCountryCode>Austria</gtr:currCountryCode><gtr:currLang>de_AT</gtr:currLang><gtr:description>ICE - International Collaborative Effort for DMD</gtr:description><gtr:end>2011-08-02</gtr:end><gtr:fundingOrg>Monaco Association against Duchenne Muscular Dystrophy</gtr:fundingOrg><gtr:id>67EA5A9C-B407-478F-888E-D2E54F68F45A</gtr:id><gtr:outcomeId>2AA346D1EDD1</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2008-10-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>65000</gtr:amountPounds><gtr:country>France, French Republic</gtr:country><gtr:currCode>EUR</gtr:currCode><gtr:currCountryCode>Austria</gtr:currCountryCode><gtr:currLang>de_AT</gtr:currLang><gtr:description>ICE - International Collaborative Effort for DMD</gtr:description><gtr:end>2011-08-02</gtr:end><gtr:fundingOrg>Duchenne Parent Project France (DPPF)</gtr:fundingOrg><gtr:id>DF7948DA-52C3-44DE-9D71-B0413728EC7A</gtr:id><gtr:outcomeId>2AA346D1EDD0</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2008-10-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>15000</gtr:amountPounds><gtr:country>France, French Republic</gtr:country><gtr:currCode>EUR</gtr:currCode><gtr:currCountryCode>Austria</gtr:currCountryCode><gtr:currLang>de_AT</gtr:currLang><gtr:description>ICE - International Collaborative Effort for DMD</gtr:description><gtr:end>2013-12-02</gtr:end><gtr:fundingOrg>Duchenne Parent Project France (DPPF)</gtr:fundingOrg><gtr:id>6163BD9A-D47D-41CB-9084-60BE22E73599</gtr:id><gtr:outcomeId>kQNtorecxqV</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2013-07-01</gtr:start></gtr:furtherFundingOutput></gtr:furtherFundingOutputs><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs/><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs/><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication><gtr:id>01F7DEBE-17EE-4983-B144-7304BAE227A8</gtr:id><gtr:title>Therapeutic approaches to muscular dystrophy.</gtr:title><gtr:parentPublicationTitle>Human molecular genetics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/41bda94ef4fcc68a41437c11403d7f83"><gtr:id>41bda94ef4fcc68a41437c11403d7f83</gtr:id><gtr:otherNames>Goyenvalle A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0964-6906</gtr:issn><gtr:outcomeId>pm_13072_22_21436158</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>989BF5C3-8DC3-43BE-AD4B-7DD746CF9762</gtr:id><gtr:title>Prevention of dystrophic pathology in severely affected dystrophin/utrophin-deficient mice by morpholino-oligomer-mediated exon-skipping.</gtr:title><gtr:parentPublicationTitle>Molecular therapy : the journal of the American Society of Gene Therapy</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/41bda94ef4fcc68a41437c11403d7f83"><gtr:id>41bda94ef4fcc68a41437c11403d7f83</gtr:id><gtr:otherNames>Goyenvalle A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>1525-0016</gtr:issn><gtr:outcomeId>687F314885D</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>3249E824-72D1-4FA2-98A4-93268C74028F</gtr:id><gtr:title>Enhanced exon-skipping induced by U7 snRNA carrying a splicing silencer sequence: Promising tool for DMD therapy.</gtr:title><gtr:parentPublicationTitle>Molecular therapy : the journal of the American Society of Gene Therapy</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/41bda94ef4fcc68a41437c11403d7f83"><gtr:id>41bda94ef4fcc68a41437c11403d7f83</gtr:id><gtr:otherNames>Goyenvalle A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>1525-0016</gtr:issn><gtr:outcomeId>8918953E2D6</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>9CD3DCD4-E84A-4B18-BCAB-297A2C153DF7</gtr:id><gtr:title>The Cellular Processing Capacity Limits the Amounts of Chimeric U7 snRNA Available for Antisense Delivery.</gtr:title><gtr:parentPublicationTitle>Molecular therapy. Nucleic acids</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/edcaff336b5cbb280931ae09d77afbaf"><gtr:id>edcaff336b5cbb280931ae09d77afbaf</gtr:id><gtr:otherNames>Eckenfelder A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:outcomeId>544638e1cd3eb0.15823838</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>7E2290A8-1170-419F-9A8A-85098A3353E0</gtr:id><gtr:title>Utrophin influences mitochondrial pathology and oxidative stress in dystrophic muscle.</gtr:title><gtr:parentPublicationTitle>Skeletal muscle</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/d10fd91cdc7201aaa60ac2a3d84e59e4"><gtr:id>d10fd91cdc7201aaa60ac2a3d84e59e4</gtr:id><gtr:otherNames>Kennedy TL</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>2044-5040</gtr:issn><gtr:outcomeId>5a7c05a8a611c2.54718527</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>41186639-C1B9-4595-AB47-23354870C08C</gtr:id><gtr:title>Therapy for Duchenne muscular dystrophy: renewed optimism from genetic approaches.</gtr:title><gtr:parentPublicationTitle>Nature reviews. Genetics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/9a6cbf20c5cc231809c413715c6e77d8"><gtr:id>9a6cbf20c5cc231809c413715c6e77d8</gtr:id><gtr:otherNames>Fairclough RJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1471-0056</gtr:issn><gtr:outcomeId>pm_13072_22_23609411</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>45C2D97E-8844-4E90-BE60-1AA455EFE13D</gtr:id><gtr:title>Engineering exon-skipping vectors expressing U7 snRNA constructs for Duchenne muscular dystrophy gene therapy.</gtr:title><gtr:parentPublicationTitle>Methods in molecular biology (Clifton, N.J.)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/41bda94ef4fcc68a41437c11403d7f83"><gtr:id>41bda94ef4fcc68a41437c11403d7f83</gtr:id><gtr:otherNames>Goyenvalle A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>1064-3745</gtr:issn><gtr:outcomeId>pm_13072_22_21194028</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>E3D6DAD9-1CC1-416B-BFDC-30DC568FDE7B</gtr:id><gtr:title>Engineering multiple U7snRNA constructs to induce single and multiexon-skipping for Duchenne muscular dystrophy.</gtr:title><gtr:parentPublicationTitle>Molecular therapy : the journal of the American Society of Gene Therapy</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/41bda94ef4fcc68a41437c11403d7f83"><gtr:id>41bda94ef4fcc68a41437c11403d7f83</gtr:id><gtr:otherNames>Goyenvalle A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>1525-0016</gtr:issn><gtr:outcomeId>54463a58bb12b6.36785921</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>CA73CADE-17EE-4D34-8DAF-1C528E6F48CD</gtr:id><gtr:title>Translating the genomics revolution: the need for an international gene therapy consortium for monogenic diseases.</gtr:title><gtr:parentPublicationTitle>Molecular therapy : the journal of the American Society of Gene Therapy</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/c745e5f96e2db4ca9a165bd1a95a4858"><gtr:id>c745e5f96e2db4ca9a165bd1a95a4858</gtr:id><gtr:otherNames>Tremblay JP</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1525-0016</gtr:issn><gtr:outcomeId>pm_13072_22_23369965</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>32973EBB-5B5F-474A-93F9-2563688E95B8</gtr:id><gtr:title>AAV genome loss from dystrophic mouse muscles during AAV-U7 snRNA-mediated exon-skipping therapy.</gtr:title><gtr:parentPublicationTitle>Molecular therapy : the journal of the American Society of Gene Therapy</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/fa0ff166301e1cc2c515b55f4eeda062"><gtr:id>fa0ff166301e1cc2c515b55f4eeda062</gtr:id><gtr:otherNames>Le Hir M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1525-0016</gtr:issn><gtr:outcomeId>54463679b69670.64770028</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>5E068A5C-0797-4F13-94CE-48D4BEB04D6C</gtr:id><gtr:title>Current status of pharmaceutical and genetic therapeutic approaches to treat DMD.</gtr:title><gtr:parentPublicationTitle>Molecular therapy : the journal of the American Society of Gene Therapy</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/5a748805ac0a6b7de4197af4677103ad"><gtr:id>5a748805ac0a6b7de4197af4677103ad</gtr:id><gtr:otherNames>Pichavant C</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>1525-0016</gtr:issn><gtr:outcomeId>pm_13072_22_21468001</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>BC8559B7-843F-40D9-AECC-17CD0955C888</gtr:id><gtr:title>Challenges to oligonucleotides-based therapeutics for Duchenne muscular dystrophy.</gtr:title><gtr:parentPublicationTitle>Skeletal muscle</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/41bda94ef4fcc68a41437c11403d7f83"><gtr:id>41bda94ef4fcc68a41437c11403d7f83</gtr:id><gtr:otherNames>Goyenvalle A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>2044-5040</gtr:issn><gtr:outcomeId>pm_13072_22_21798085</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>C65B24B2-E10B-499C-B5DB-062D04343EB5</gtr:id><gtr:title>Rescue of severely affected dystrophin/utrophin-deficient mice through scAAV-U7snRNA-mediated exon skipping.</gtr:title><gtr:parentPublicationTitle>Human molecular genetics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/41bda94ef4fcc68a41437c11403d7f83"><gtr:id>41bda94ef4fcc68a41437c11403d7f83</gtr:id><gtr:otherNames>Goyenvalle A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0964-6906</gtr:issn><gtr:outcomeId>544639f18be399.66066317</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>14A8C8B7-466F-4A92-BD59-06AA9D966083</gtr:id><gtr:title>Pharmacological advances for treatment in Duchenne muscular dystrophy.</gtr:title><gtr:parentPublicationTitle>Current opinion in pharmacology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/52b4babf7b22c1bb650c3b41a2537d52"><gtr:id>52b4babf7b22c1bb650c3b41a2537d52</gtr:id><gtr:otherNames>Guiraud S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>1471-4892</gtr:issn><gtr:outcomeId>5a6f2ffe815238.41073452</gtr:outcomeId></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">G0801763</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>149FA87E-B8CD-4FFC-B515-EAD312BED03B</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>Musculoskeletal</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>DD81206B-5EB4-4BCC-AEF7-808A64606E0E</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>5.2  Cellular and gene therapies</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>